Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triglyceride
Biotech
Arrowhead posts phase 3 data ahead of market clash with Ionis
Arrowhead has shown its hand ahead of a showdown with Ionis, publishing phase 3 data on a rare metabolic disease drug that is racing to regulators.
Nick Paul Taylor
Sep 3, 2024 9:27am
Arrowhead RNAi med lowers triglycerides in phase 3
Jun 3, 2024 9:54am
Arrowhead on target in lipid disorder as it pursues Ionis
Apr 8, 2024 9:37am
Acasti abandons omega-3 filing after 2nd phase 3 flop
Sep 1, 2020 9:20am
Akcea, Pfizer hit midphase goal, but data raise doubts
Jan 29, 2020 7:10am
With phase 2 success, Akcea to test triglyceride-buster in FCS
Jan 22, 2020 10:34am
